Tet-Off Advanced human stably expressing high-transition nasopharyngeal carcinoma cell line S18, construction method thereof and application thereof
A technology with stable expression and high metastasis, applied in the field of genetic engineering, can solve the problem of application of nasopharyngeal cancer cells without tet-offadvanced system, and achieve the effect of sensitive and effective regulation, high accuracy, real-time timing and quantitative regulation
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0041] Construction of human highly metastatic nasopharyngeal carcinoma cell line S18 stably expressing Tet-Off Advanced:
[0042] (1) Plasmid preparation: transform pTet-Off Advanced into JM109 competent bacteria, pick a single clone and amplify it, use the endotoxin-free plasmid extraction kit, extract 200 μg of plasmid, and take 10~50 μg of pTet-Off Advanced plasmid After digestion with 5μl-25μl restriction endonuclease ScaI for 2 hours, precipitate with alcohol.
[0043] (2) Cultivation of nasopharyngeal carcinoma cells: Nasopharyngeal carcinoma cell S18 was cultured in DMEM medium containing 10% fetal bovine serum for future use.
[0044] (3) Cell transfection: cells were cultured in a 24-well plate, and when the cell adhesion area reached 90% to 95%, 0.5 μl liposome and 0.8 μg pTet-Off Advanced plasmid per well were mixed and transfected in optimized serum. dye. At this time, the culture medium is 0.5ml.
[0045] (4) Screening of stable cell lines: after 48 hours of t...
Embodiment 2
[0053] A nasopharyngeal carcinoma cell line induced to express luciferase (Luc) was constructed on the basis of the human highly metastatic nasopharyngeal carcinoma cell line S18 stably expressing Tet-Off Advanced obtained in Example 1.
[0054] The S18Tet-Off Advanced cell line obtained in Example 1 with a 42-fold difference in expression fold was selected. pTRE-Tight-Luc was linearized with the restriction endonuclease ScaI, mixed with the genetic resistance gene hygromycin B DNA fragment at a molar ratio of 20:1, and transfected into S18Tet-Off Advanced cells with Invitrogen Lipofectamine 2000 liposomes , the transfection conditions were as in step (3) of Example 1. The medium was changed 6 hours after transfection, Dox was added to one part to make the final concentration 1 μg / ml, and Dox was not added to the other part. For transient detection, 48 hours after transfection, by luciferase analysis, the expression intensity without Dox is 42-250 times that of Dox. For stab...
Embodiment 3
[0058] Example 2 On the basis of the human highly metastatic nasopharyngeal carcinoma cell line S18 stably expressing Tet-Off Advanced obtained in Example 1, a nasopharyngeal carcinoma cell line that induces the expression of human ferritin was constructed.
[0059]The S18Tet-Off Advanced cell line obtained in Example 1 with a 42-fold difference in expression fold was selected. The reconnection (FTH) of the cloned human ferritin gene was cloned into the pTRE-Tight-BI-Luc plasmid to construct pTRE-Tight-BI-Luc-FTH after sequencing without mutation. The latter was linearized with the restriction endonuclease ScaI, mixed with the quality of the genetic resistance gene hygromycin B DNA fragment at 20:1, and transfected into S18 Tet-Off Advanced cells with Invitrogen Lipofectaime 2000 liposomes as the carrier. The transfection conditions As embodiment 1 step (3). The medium was changed 6 hours after transfection, Dox was added to one part to make the final concentration 1 μg / ml (+...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com